The companies didn't start a big trial testing whether adding Zetia to Zocor prevents heart attacks and strokes until three years after the drug was approved for sale.
That drug was linked in several analyses of published data to an increase in the risk of heart attacks, but big studies didn't provide a clear answer as to whether the risk was real.